Skip to main content
. 2019 May 6;8(5):418. doi: 10.3390/cells8050418

Table 1.

Summary of PDX clinical trials.

Author Year1 Origin2 Cases3 Strain4 Site5 Animals6
Hammer [18] 2010 NSCLC7 22 Nude sc12 6
Bertotti [20] 2011 CRC8 85 NOD-scid sc12 6
Laheru [22] 2012 Pancreas 14 Nude sc12 5
Amendt [25] 2014 NSCLC7 45 Nude sc12 10
Chen [41] 2015 CRC8 27 Nude sc12 5
Gao [10] 2015 Solid tumor 1075 Nude sc12 1
Pan [50] 2015 Bladder 22 NSG sc12/ortho13 8 to 10
Guo [56] 2016 CRC8 25 NSG sc12 Unknown
Gupta [57] 2016 GBM9 28 Nude ortho13 8 to 10
Bialucha [67] 2017 Ovary/RCC10 30 Nude sc12 1
Yao [87] 2017 CRC 79 Nude sc12 1
Einarsdottir [96] 2018 Melanoma 31 NOG sc12 1
Ruicci [107] 2018 HNSCC11 20 NSG sc12 2
Zhong [113] 2019 Breast/Ovary 23 Nude sc12 2 to 3

1 Publication year. 2 Origin of cancer for PDX models. 3 Number of PDX models. 4 Mouse strain. 5 Implantation site. 6 Number of animals per each treatment group. 7 Non-small cell lung cancer. 8 Colorectal cancer. 9 Glioblastoma. 10 Renal cell carcinoma. 11 Head and neck squamous cell carcinoma. 12 Subcutaneously implantation. 13 Orthotopic implantation.